A Chinese biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases globally.
Employees: 1-10
Total raised: $250M
Investors 3
| Date | Name | Website |
| - | OrbiMed | orbimed.co... |
| - | 3H Health ... | 3hhinvestm... |
| 25.12.2024 | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 05.02.2026 | - | $130M | - |
| 13.12.2024 | Series C | $120M | - |
Mentions in press and media 11
| Date | Title | Description |
| 05.02.2026 | Angitia raises $130M to challenge Amgen with bone-building bispecifics | Angitia Biopharmaceuticals has unveiled its second megaround in 14 months, revealing a $130 million series D financing that positions the biotech to take three bone disease prospects deeper into the clinic. Led by people who learned the bon... |
| 13.12.2024 | Angitia Biopharmaceuticals: $120 Million (Series C) Raised To Develop Therapeutics For Serious Musculoskeletal Diseases | Angitia Biopharmaceuticals – a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics for serious musculoskeletal diseases – announced the closing of a $120 million Series C financing round. Bain ... |
| 12.12.2024 | Angitia Biopharmaceuticals Secures $120 Million to Tackle Musculoskeletal Diseases | In the bustling world of biotechnology, funding is the lifeblood that keeps innovation alive. Angitia Biopharmaceuticals, a clinical-stage company based in Woodland Hills, California, has just secured a hefty $120 million in Series C financ... |
| 12.12.2024 | Bain Capital leads $120m Series C for Angitia Biopharma | Angitia Biopharmaceuticals, a clinical-stage biotech firm with operations in the US and China, has secured $120 million in a Series C round of financing led by Bain Capital Life Sciences. |
| 11.12.2024 | Angitia Biopharmaceuticals Announces $120 Million Series C Financing | - Financing led by Bain Capital Life Sciences with significant participation from existing and new investors - Proceeds will support the development of AGA2118, AGA2115, AGA111 and other pipeline assets for the treatment of serious musculos... |
| 11.12.2024 | Angitia raises $120M series C to fund trio of musculoskeletal trials | Less than a year after completing a series B extension round, Angitia Biopharmaceuticals has set its sights even higher with a $120 million series C that the biotech will use to push its three musculoskeletal candidates through ongoing tria... |
| 11.12.2024 | Angitia Biopharmaceuticals Nets $120 Million Series C Financing | WOODLAND HILLS, CA, Angitia Biopharmaceuticals, a clinical-stage biotechnology company, announced the closing of a $120 million Series C financing round. >> Click here for more funding data on Angitia Biopharmaceuticals >> To e... |
| 11.12.2024 | Angitia Biopharmaceuticals Raises $120M in Series C Funding | Angitia Biopharmaceuticals, a Woodland Hills, CA-based biotech focused on serious musculoskeletal diseases, raised $120M in Series C funding. The round was led by Bain Capital Life Sciences with participation from Janus Henderson and OrbiMe... |
| 26.10.2023 | Deals in brief: YouTrip secures Series B funding, Kopital Ventures completes first close of maiden fund, three China deals, and more | YouTrip secures USD 50 million in Series B funding The Singapore-based fintech company has secured USD 50 million in a Series B funding round led by Lightspeed, adding to the USD 25.5 million and USD 30 million previously raised by the comp... |
| 25.10.2023 | Angitia Biopharma snags $46m and 48 more Greater China deals worth $1b | Biotech firm Angitia Biopharmaceuticals has snagged $46 million in a Series B extension round led by Morningside Ventures, according to a company announcement on October 19. Morningside, founded in 1986 by Hong Kong property tycoon Ronnie C... |
Show more